Researchers now recognize eight different trajectories after COVID infection; some are severely ill many months later.
According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors. EYE PCR’s fixOflex is now eligible for European ...